• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CHA2DS2-VASc评分对药物洗脱支架植入患者支架内再狭窄的预测价值

The Predictive Value of the CHA2DS2-VASc Score for In-Stent Restenosis Among Patients with Drug-Eluting Stents Implantation.

作者信息

Zhao Jinbo, Hou Ling, Zhu Ni, Huang Rui, Su Ke, Lei Yuhua, Li Yuanhong

机构信息

Cardiovascular Disease Center, Central Hospital of Tujia and Miao Autonomous Prefecture, Hubei University of Medicine, Enshi Prefecture, Hubei Province, 445000, People's Republic of China.

Department of Central Hospital of Tujia and Miao Autonomous Prefecture, Hubei University of Medicine, Shiyan, Hubei Province, 442000, People's Republic of China.

出版信息

Int J Gen Med. 2023 Jan 5;16:69-76. doi: 10.2147/IJGM.S391312. eCollection 2023.

DOI:10.2147/IJGM.S391312
PMID:36636712
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9830419/
Abstract

OBJECTIVE

The CHA2DS2-VASc score, a system which has been initially recommended for the assessment of thromboembolic risk in patients with atrial fibrillation (AF), arouses attention in the field of adverse coronary events. The purpose of this study was to explore the predictive value of preprocedural CHA2DS2-VASc score on ISR in patients after drug-eluting stent (DES) implantation.

METHODS

To further investigate the relationship between CHA2DS2-VASc scores and ISR after DES, a retrospective study of DES was carried on. Additionally, the preoperative variables for the ISR and control groups were contrasted. Predictive factors were chosen using the optimal subset regression. We validate the model using internal validation. The prediction model was evaluated using the receiver operator characteristic (ROC) analysis.

RESULTS

We used a 3:7 ratio to create an experimental group and a validation group, and then ran a stepwise regression with the data from each of the two groups. The results showed that CHA2DS2-VASc score was an independent risk factor for ISR in both the experimental (p = 0.0139) and validation groups (p = 0.0014), and both had significant predictive value for ISR. The area of the ROC curve was greater than 0.5 in both groups (AUC = 0.78, 0.719, respectively) indicating that the model fit was good in both groups.

CONCLUSION

The CHA2DS2-VASc score is a reliable predictor of in-stent restenosis (ISR) after DES implantation.

摘要

目的

CHA2DS2-VASc评分系统最初被推荐用于评估心房颤动(AF)患者的血栓栓塞风险,目前在不良冠状动脉事件领域引起了关注。本研究的目的是探讨术前CHA2DS2-VASc评分对药物洗脱支架(DES)植入术后患者支架内再狭窄(ISR)的预测价值。

方法

为进一步研究DES术后CHA2DS2-VASc评分与ISR之间的关系,对DES进行了回顾性研究。此外,对比了ISR组和对照组的术前变量。使用最优子集回归选择预测因素。我们使用内部验证对模型进行验证。使用受试者工作特征(ROC)分析对预测模型进行评估。

结果

我们以3:7的比例创建了一个实验组和一个验证组,然后对两组的数据进行逐步回归。结果显示,CHA2DS2-VASc评分在实验组(p = 0.0139)和验证组(p = 0.0014)中均为ISR的独立危险因素,且对ISR均具有显著的预测价值。两组的ROC曲线面积均大于0.5(AUC分别为0.78、0.719),表明两组模型拟合良好。

结论

CHA2DS2-VASc评分是DES植入术后支架内再狭窄(ISR)的可靠预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/502a/9830419/bc825d82c137/IJGM-16-69-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/502a/9830419/20fca1928624/IJGM-16-69-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/502a/9830419/1288f8f500b3/IJGM-16-69-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/502a/9830419/bc825d82c137/IJGM-16-69-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/502a/9830419/20fca1928624/IJGM-16-69-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/502a/9830419/1288f8f500b3/IJGM-16-69-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/502a/9830419/bc825d82c137/IJGM-16-69-g0003.jpg

相似文献

1
The Predictive Value of the CHA2DS2-VASc Score for In-Stent Restenosis Among Patients with Drug-Eluting Stents Implantation.CHA2DS2-VASc评分对药物洗脱支架植入患者支架内再狭窄的预测价值
Int J Gen Med. 2023 Jan 5;16:69-76. doi: 10.2147/IJGM.S391312. eCollection 2023.
2
CHADS-Vasc score and CHADS-Vasc-HS score are poor predictors of in-stent restenosis among patients with coronary drug-eluting stents.CHADS-Vasc评分和CHADS-Vasc-HS评分在接受冠状动脉药物洗脱支架治疗的患者中,对支架内再狭窄的预测能力较差。
J Int Med Res. 2019 Jun;47(6):2533-2544. doi: 10.1177/0300060519841836. Epub 2019 Apr 30.
3
Evaluation of the Predictive Value of CHADS-VASc Score for In-Stent Restenosis.CHADS-VASc评分对支架内再狭窄的预测价值评估
Angiology. 2018 Jan;69(1):38-42. doi: 10.1177/0003319717700746. Epub 2017 Mar 27.
4
Usefulness of the CHA2DS2-VASc Score in Predicting In-Stent Restenosis Among Patients Undergoing Revascularization With Bare-Metal Stents.CHA2DS2-VASc评分在预测接受裸金属支架血管重建术患者支架内再狭窄中的应用价值。
Clin Appl Thromb Hemost. 2018 May;24(4):589-595. doi: 10.1177/1076029617716769. Epub 2017 Jul 4.
5
Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.二代药物洗脱支架置入术后三血管病变患者血运重建和支架内再狭窄的危险因素:回顾性分析。
BMC Cardiovasc Disord. 2021 Sep 17;21(1):446. doi: 10.1186/s12872-021-02259-0.
6
Importance and usage of the CHA2DS2-VASc score in predicting acute stent thrombosis.CHA2DS2-VASc评分在预测急性支架血栓形成中的重要性及应用
Coron Artery Dis. 2016 Sep;27(6):478-82. doi: 10.1097/MCA.0000000000000388.
7
Prognostic Role of Fasting Remnant Cholesterol with In-Stent Restenosis After Drug-Eluting Stent Implantation.空腹残余胆固醇在药物洗脱支架植入术后支架内再狭窄中的预后作用
Int J Gen Med. 2022 Feb 18;15:1733-1742. doi: 10.2147/IJGM.S348148. eCollection 2022.
8
Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention.慢性阻塞性肺疾病史对经皮冠状动脉介入治疗后冠状动脉支架内再狭窄的预测价值
Int J Gen Med. 2023 Aug 31;16:3977-3984. doi: 10.2147/IJGM.S427425. eCollection 2023.
9
Risk investigation of in-stent restenosis after initial implantation of intracoronary drug-eluting stent in patients with coronary heart disease.冠心病患者冠状动脉药物洗脱支架初次植入后支架内再狭窄的风险调查
Front Cardiovasc Med. 2023 Mar 10;10:1117915. doi: 10.3389/fcvm.2023.1117915. eCollection 2023.
10
Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗患者支架内再狭窄风险预测列线图的建立与验证。
BMC Cardiovasc Disord. 2021 Sep 14;21(1):435. doi: 10.1186/s12872-021-02255-4.

本文引用的文献

1
Prognostic Role of Fasting Remnant Cholesterol with In-Stent Restenosis After Drug-Eluting Stent Implantation.空腹残余胆固醇在药物洗脱支架植入术后支架内再狭窄中的预后作用
Int J Gen Med. 2022 Feb 18;15:1733-1742. doi: 10.2147/IJGM.S348148. eCollection 2022.
2
Association of CHADS-VASc score with thrombus burden in patients with acute myocardial infarction undergoing SVG-PCI.CHADS-VASc 评分与急性心肌梗死患者行 SVG-PCI 术后血栓负荷的相关性研究。
Herz. 2022 Oct;47(5):456-464. doi: 10.1007/s00059-021-05070-x. Epub 2021 Oct 4.
3
A New Current to The Armamentarium: Is the CHA2DS2-Vasc-HS Score Predictive of Low Left Internal Mammary Artery (LIMA) Flow in Patients Underwent Coronary Bypass Surgery?
一种新的武器库:CHA2DS2-Vasc-HS 评分是否可预测行冠状动脉旁路移植术患者的左内乳动脉(LIMA)低流量?
Heart Surg Forum. 2021 Jul 27;24(4):E631-E636. doi: 10.1532/hsf.3837.
4
Drug-Coated Balloons versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis: A Pair-Wise Meta-Analysis of Randomized Trials.药物涂层球囊与依维莫司洗脱支架治疗支架内再狭窄患者的比较:随机试验的成对荟萃分析。
Cardiovasc Ther. 2020 Jan 21;2020:1042329. doi: 10.1155/2020/1042329. eCollection 2020.
5
A guide for Gensini Score calculation.Gensini评分计算指南。
Atherosclerosis. 2019 Aug;287:181-183. doi: 10.1016/j.atherosclerosis.2019.05.012. Epub 2019 May 10.
6
Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials.药物洗脱支架或金属裸支架经皮冠状动脉介入治疗:随机临床试验的系统评价和个体患者数据分析荟萃分析。
Lancet. 2019 Jun 22;393(10190):2503-2510. doi: 10.1016/S0140-6736(19)30474-X. Epub 2019 May 2.
7
Epidemiology of cardiovascular disease in China: current features and implications.中国心血管疾病的流行病学:现状特征及影响。
Nat Rev Cardiol. 2019 Apr;16(4):203-212. doi: 10.1038/s41569-018-0119-4.
8
Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.心血管益处备受关注:将2型糖尿病治疗模式转向对明显心血管疾病患者进行早期联合治疗。
Cardiovasc Diabetol. 2018 Aug 22;17(1):117. doi: 10.1186/s12933-018-0760-6.
9
CHADS-VAS Clinical Score to Predict In-Stent Restenosis.预测支架内再狭窄的CHADS-VAS临床评分
Angiology. 2018 Sep;69(8):653-656. doi: 10.1177/0003319717736159. Epub 2017 Nov 1.
10
Diagnosis and management challenges of in-stent restenosis in coronary arteries.冠状动脉支架内再狭窄的诊断与管理挑战
World J Cardiol. 2017 Aug 26;9(8):640-651. doi: 10.4330/wjc.v9.i8.640.